미국의 방사선피부염 시장 규모, 점유율, 동향 분석 리포트 : 제품 유형별, 유통 채널별, 시설 유형별, 부문별 예측(2024-2030년)

U.S. Radiodermatitis Market Growth & Trends:

The U.S. radiodermatitis market size is expected to reach USD 481.07 million by 2030, growing at a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several key factors, including the increasing prevalence of cancer, advancements in radiation therapy techniques, and the development of new treatment options for radiodermatitis are contributing to this growth. The growing burden of cancer is a significant factor driving market growth. With cancer being one of the leading causes of death worldwide, the demand for effective radiation therapy and subsequent management of radiodermatitis is growing. The high incidence of cancer types, such as breast and prostate cancers, which often require radiation therapy, is expected to boost market expansion. Moreover, the growing geriatric population, which is more susceptible to chronic diseases such as cancer, is boosting the demand for radiodermatitis treatment.

The market growth is also affected by the development of new treatment options for radiodermatitis, such as topical creams, dressings, and oral medications, which has expanded the market scope. Although these innovations offer patients more choices in managing their symptoms and potentially lead to improved quality of life & reduced healthcare costs associated with severe cases of radiodermatitis, they may also reduce the demand for traditional radiodermatitis management solutions. For instance, in April 2024, Molnlycke announced an agreement to acquire P.G.F. Industry Solutions GmbH, a prominent wound cleansing manufacturer. This acquisition is expected to help the company strengthen its position as a global leader in wound care.

Moreover, growth is also influenced by the increasing awareness and education among healthcare professionals & patients regarding the importance of managing radiodermatitis. This awareness has led to a greater emphasis on preventive measures and early intervention, which are crucial in minimizing the severity of radiodermatitis & improving patient outcomes. Collaborations between healthcare providers, researchers, and pharmaceutical companies to develop & promote effective radiodermatitis treatments further drive market expansion. Thus, the combined impact of the increasing prevalence of cancer, advancements in radiation therapy & treatment options, and the growing awareness & education about radiodermatitis management is expected to contribute to industry growth.

U.S. Radiodermatitis Market Report Highlights:

• The topical product segment accounted for a revenue share of 75.68% in 2023. This share can be attributed to the widespread use of topical products in managing the symptoms of radiodermatitis.
• Topical treatments, including creams & ointments, can be directly applied to the affected area, providing immediate relief and reducing the risk of systemic adverse effects.
• The retail pharmacies segment held the largest revenue share in 2023. This growth can be attributed to their accessibility and convenience. Retail pharmacies serve as a primary point of contact for many patients seeking over-the-counter treatments for conditions such as radiodermatitis.
• The independent radiotherapy centers segment held the largest revenue share in 2023. This is due to their focus on advanced radiotherapy treatments, reduced radiation exposure, and increased precision in tumor targeting. Moreover, these centers often have a more personalized approach, which can lead to higher patient satisfaction and repeat business.
• Market players are undertaking various strategic initiatives to enhance product reach and availability across different geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Distribution channel
  • 1.2.3. Facility type
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. Epidemiology-based Market Analysis
  • 1.8.1. Research Scope and Assumptions
  • 1.8.2. Research Methodology and Assumptions
• 1.9. List of Secondary Sources
• 1.10. List of Primary Sources
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product
  • 2.2.2. Distribution channel
  • 2.2.3. Facility type
• 2.3. Competitive Insights

Chapter 3. U.S. Radiodermatitis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Related/ancillary market outlook
• 3.2. Prevalence of Different Cancer Types in the U.S.
• 3.3. Incidence and Mortality Rates of Different Cancer Types in the U.S. in 2024
• 3.4. Expected Cancer Incidence in the U.S. for 2024 (by States)
• 3.5. Number of Patients Opting for Radiation Therapy and Suffering From Radiodermatitis in the U.S. in 2024
• 3.6. Grades of Radiodermatitis for Different Cancer Types
• 3.7. Characterization of Radiodermatitis for Cancer Using Clinical Parameters
• 3.8. Facility Types for Radiation Therapy (for Different Types of Cancer in the U.S.)
• 3.9. Average Product Cost for Radiodermatitis Treatment
• 3.10. Product Market Opportunities
• 3.11. Market Dynamics
  • 3.11.1. Market driver Analysis
    • 3.11.1.1. Increasing cancer incidence
    • 3.11.1.2. Advancements in radiation therapy
  • 3.11.2. Market restraint analysis
    • 3.11.2.1. High cost of treatment
• 3.12. U.S. Radiodermatitis Market Analysis Tools
  • 3.12.1. Industry Analysis - Porter's
    • 3.12.1.1. Supplier power
    • 3.12.1.2. Buyer power
    • 3.12.1.3. Substitution threat
    • 3.12.1.4. Threat of new entrant
    • 3.12.1.5. Competitive rivalry
  • 3.12.2. PESTEL Analysis
    • 3.12.2.1. Political landscape
    • 3.12.2.2. Technological landscape
    • 3.12.2.3. Economic landscape

Chapter 4. U.S. Radiodermatitis Market: Product Estimates & Trend Analysis

• 4.1. U.S. Radiodermatitis Market: Product Dashboard
• 4.2. U.S. Radiodermatitis Market: Product Movement Analysis
• 4.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Topical
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.1. Corticosteroids
    • 4.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Hydrophilic Creams
    • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Antibiotics
    • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Others
    • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Dressings
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.1. Hydrogel and Hydrocolloid Dressings
    • 4.5.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.2. No Sting Barrier Films
    • 4.5.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.3. Honey-Impregnated Gauze
    • 4.5.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.4. Silicone-Coated Dressings
    • 4.5.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.5. Others
    • 4.5.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis

• 5.1. U.S. Radiodermatitis Market: Distribution Channel Dashboard
• 5.2. U.S. Radiodermatitis Market: Distribution Channel Movement Analysis
• 5.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Online Pharmacies
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Radiodermatitis Market: Facility Type Estimates & Trend Analysis

• 6.1. U.S. Radiodermatitis Market: Facility Type Dashboard
• 6.2. U.S. Radiodermatitis Market: Facility Type Movement Analysis
• 6.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Facility Type, 2018 to 2030 (USD Million)
• 6.4. Hospital-based Radiotherapy Centers
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Independent Radiotherapy Centers
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Stratpharma AG
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Type benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Smith & Nephew plc
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Type benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. Molnlycke Health Care AB
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Type benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Derma Sciences Inc
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Type benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Convatec Inc
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Type benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. 3M Company
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Type benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Alliqua BioMedical
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Type benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. BMG Pharma spA
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Type benchmarking
    • 7.3.9.4. Strategic initiatives